Form 6-K ASTRAZENECA PLC For: Feb 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
AstraZeneca (AZN) Misses Q3 EPS by 9c
February 5, 2015 8:49 AM ESTAstraZeneca (NYSE: AZN) reported Q3 EPS of $0.76, $0.09 worse than the analyst estimate of $0.85. Revenue for the quarter came in at $6.68 billion versus the consensus estimate of $6.68 billion.
Pascal Soriot, Chief Executive Officer, commenting on the results, said:
2014 was a remarkable year for AstraZeneca. We achieved a record six product... More
